SavedAdd your journal

Journals / Türk Patoloji Dergisi / 2012 / Cilt: 28 - Sayı: 1

Suudi Arabistan’da invaziv meme kanserlerinde her-2 neu protein ekspresyonu ve hormon reseptörlerinin ilişkisi

Correlation of hormone receptors with her-2 neu protein expression and the histological grade in ınvasive breast cancers in a cohort of Saudi Arabia

Maha ARAFAH
Pages
38–43
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: The expression of Estrogen Receptor, Progesterone Receptor were significantly correlated (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Data on Hormone Receptor and Her-2/neu expression in breast cancers from Saudi Arabia and Gulf Region is sparse.
📊
Key Findings & Data:We undertook this study to describe the patterns of hormone receptor and Her-2/neu protein expression in breast carcinoma and compared them with the histological grade at a University Hospital in Riyadh.
💡
Conclusion & Impact:Results: The expression of Estrogen Receptor, Progesterone Receptor were significantly correlated (p
🔬Design:Research Article
📍Scope:2002 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Data on Hormone Receptor and Her-2/neu expression in breast cancers from Saudi Arabia and Gulf Region is sparse. We undertook this study to describe the patterns of hormone receptor and Her-2/neu protein expression in breast carcinoma and compared them with the histological grade at a University Hospital in Riyadh. Material and Method: We conducted a retrospective study on 164 invasive ductal carcinoma of breast between the year 2002 and 2008. Immunohistochemical analysis for Estrogen and Progesterone Receptor and Her-2/neu was done in all the cases. Fluorescent in situ hybridization for Her-2/neu gene amplification was performed in all 2+ cases and few equivocal 1+ and 3+cases by immunohistochemistry. Correlation between Estrogen and Progesterone Receptor and Her-2/ neu amplification and grade of tumor was calculated. Results: The expression of Estrogen Receptor, Progesterone Receptor were significantly correlated (p

Özet

Amaç: Suudi Arabistan ve Körfez bölgesinde meme kanserlerinde hormon reseptörleri ve Her-2/neu ekspresyonu ile ilgili veri azdır. Bu çalışmada, Riyad Üniversite Hastanesi'nde meme kanserlerinde hormon reseptörleri ve Her-2/neu ekspresyonu paternleri tanımlanmaktadır. Gereç ve Yöntem: Retrospektif olarak, 2002-2008 yılları arasında tanı alan 164 invaziv duktal karsinom olgusu çalışılmıştır. İmmünohistokimyasal olarak östrojen ve progesteron reseptörü ve Her-2/neu çalışılmış, tüm 2+ olgular ve kuşkulu 1+ ve 3+ olguların bazılarında floresan in situ hibridizasyon yöntemi ile Her-2/ neu amplifikasyonu değerlendirilmiştir. Östrojen ve progesteron reseptörü ve Her-2/neu amplifikasyonu ile tümör derecesi ilişkisi değerlendirilmiştir.Bulgular: Östrojen ve progesteron reseptörü ekspresyonu ilişkili saptanmıştır (p

🔖

Cite This Article

ARAFAH, M. (2022). Suudi Arabistan’da invaziv meme kanserlerinde her-2 neu protein ekspresyonu ve hormon reseptörlerinin ilişkisi. Türk Patoloji Dergisi, Cilt: 28 - Sayı: 1, 38–43. https://ajindex.com/articles/640714

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Horita K, Yamaguchi A, Hirose K, Ishida M, Noriki S, Imamura Y, Fukuda M: Prognostic factors affecting disease-free survival rate following surgical resection of primary breast cancer. Eur J Histochem 2001, 45:73-84 2. Zafrani B, Aubriot MH, Mouret E, De Crémoux P, De Rycke Y, Nicolas A, Boudou E, Vincent-Salomon A, Magdelénat H, Sastre-Garau X: High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases. Histopathology 2000, 37: 536-545 3. Hanna W, Kahn HJ, Trudeau M: Evaluation of HER-2/neu (erbB-2) status in breast cancer: from bench to bedside. Mod Pathol 1999, 12: 827-834 4. Ross JS, Fletcher JA: The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist 1998, 3: 237-252 5. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, FitzgibbonsPL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB,McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H,Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D,Wheeler T, Williams RB, Wittliff JL, Wolff AC: American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010, 28: 2784-2795 6. Brunelli M, Manfrin E, Martignoni G, Bersani S, Remo A, Reghellin D, Chilosi M, Bonetti F: HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy. Am J Clin Pathol 2008, 129: 907-911 7. Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, Berteloot P, Amant F, Vergote I, Christiaens MR: Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer. Ann Oncol 2005, 16: 1755-1761 8. Ratnatunga N, Liyanapathirana LV: Hormone receptor expression and Her/2neu amplification in breast carcinoma in a cohort of Sri Lankans. Ceylon Med J 2007, 52: 133-136 9. Perez EA, Pusztai L, Van de Vijver M: Improving patient care through molecular diagnostics. Semin Oncol 2004, 31:14-20 10. Piccart MJ, Mano M, Lohrisch C, Di Leo A: Herceptin for the treatment of breast cancer: what we know-and what we have yet to learn. Cancer Futures 2002, 1: 73-79 11. Bast RC Jr, Ravdin P, Haye